Biodel Inc. (NSDQ:BIOD) announced the results of pre-clinical tests on its candidate for a diabetes treatment called BIOD620.
The tests indicated that the Danbury, Conn.-based company’s insulin product releases the blood-sugar-regulating hormone in response to changing glucose levels.